EP3971188A1 — Pharmaceutical composition comprising a pi3k delta selective inhibitor for use in the treatment of pi3k mediated diseases
Assigned to Rhizen Pharmaceuticals AG · Expires 2022-03-23 · 4y expired
What this patent protects
The divisional application relates to a pharmaceutical composition comprising a p-toluenesulfonic acid salt (PTSA) of the selective PI3K delta inhibitor (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chrome…
USPTO Abstract
The divisional application relates to a pharmaceutical composition comprising a p-toluenesulfonic acid salt (PTSA) of the selective PI3K delta inhibitor (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one (TGR-1202) and a solubilizer, and to the pharmaceutical composition for use in the treatment of a PI3K kinase mediated disease or disorder such as cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.